NCT06313996 2026-03-18
A Study to Evaluate the Efficacy and Safety of Liso-cel Compared to Standard of Care in Adults With Relapsed or Refractory Follicular Lymphoma
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Phase 3 Withdrawn
Clinical Trials
21 trialsNCT06068881 2026-01-30
Mandolin
Ipsen
Phase 2 Withdrawn
NCT06650839 2026-01-07
POC for the Treatment of Subjects With Moderate AS Using Valvosoft® Non-Invasive Ultrasound Therapy
Cardiawave SA
Phase NA Withdrawn
NCT07060183 2025-07-11
Aortic Valve Replacement for Moderate Aortic Stenosis With Left Ventricular Decompensation Early Feasibility Study
Dermed Diagnostics, Inc.
Phase NA Withdrawn
NCT02743546 2025-02-03
Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of Duvortuxizumab (JNJ-64052781) Plus Ibrutinib in Lymphoma
Janssen Research & Development, LLC
Phase 1 Withdrawn
NCT05125562 2024-02-13
Extracellular Vesicles Infusion Treatment for Mild-to-Moderate COVID-19
Direct Biologics, LLC
Phase 2 Withdrawn
NCT05867030 2023-10-17
Parsaclisib in Patients With Relapsed or Refractory Follicular Lymphoma
Innovent Biologics (Suzhou) Co. Ltd.
Phase 1 Withdrawn
NCT05934097 2023-07-06
FT596 in Combination With R-CHOP in Subjects With B-Cell Lymphoma
Fate Therapeutics
Phase 1 Withdrawn
NCT05176691 2023-02-21
HMPL-760 Safety and Tolerability Study in Patients With Previously Treated CLL/SLL or NHL
Hutchmed
Phase 1 Withdrawn
NCT05251376 2023-01-19
Study of LYN-014 in Individuals With Opioid Use Disorder Who Are Stable on Methadone Therapy
Lyndra Inc.
Phase 1 Withdrawn
NCT05371275 2022-11-07
CDK6COV
biotx.ai GmbH
Phase 2 Withdrawn
NCT04796922 2022-07-18
To Evaluate Efficacy and Safety of Parsaclisib Plus Either Rituximab or Obinutuzumab in R/R Follicular Lymphoma (FL) and Marginal Zone Lymphoma (MZL) (CITADEL-302)
Incyte Corporation
Phase 3 Withdrawn
NCT02576275 2021-03-17
A Study of Duvelisib in Combination With Rituximab and Bendamustine vs Placebo in Combination With Rituximab and Bendamustine in Subjects With Previously-Treated Indolent Non-Hodgkin Lymphoma (BRAVURA)
SecuraBio
Phase 3 Withdrawn
NCT00551239 2020-10-19
Fludarabine and Rituximab With or Without Pixantrone in Treating Patients With Relapsed or Refractory Indolent Non-Hodgkin Lymphoma
CTI BioPharma
Phase 3 Withdrawn
NCT02657447 2019-01-10
Dosimetry Study of Betalutin for Treatment of Relapsed Non-Hodgkin Lymphoma (LYMRIT-37-02)
Nordic Nanovector
Phase 1 Withdrawn
NCT02722551 2018-01-09
RELIEF
Edwards Lifesciences
Phase 1/2 Withdrawn
NCT02796066 2017-04-26
TSN2898-201 Safety and Efficacy of TSN2898 in the Treatment of Acne Vulgaris
Thesan Pharmaceuticals, Inc.
Phase 2 Withdrawn
NCT00092274 2015-04-21
Study of HuMax-CD20, a New Drug to Treat Early Stage Non-Hodgkin´s Follicular Lymphoma
GlaxoSmithKline
Phase 1/2 Withdrawn
NCT00319332 2015-04-17
A Comparative Study Of Iodine I 131 Tositumomab Therapeutic Regimen Versus Ibritumomab Tiuxetan Therapeutic Regimen
GlaxoSmithKline
Phase 3 Withdrawn
NCT02238522 2014-11-13
Phase 1 Study Evaluating ZEN003365 in Relapsed/Refractory Lymphoproliferative Malignancies or Relapsed/Refractory AML
Zenith Epigenetics
Phase 1 Withdrawn
NCT00711204 2012-12-10
Evaluating The Impact Of Donepezil Hydrochloride (Aricept) On Behavioral And Psychological Symptoms In Patients With Severe Alzheimer's Disease
Eisai Inc.
Phase 4 Withdrawn